Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
|ClinicalTrials.gov Identifier: NCT00004340|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
OBJECTIVES: I. Evaluate the separate and combined skeletal effects of recombinant human growth hormone (GH) and calcitriol in patients with adynamic renal osteodystrophy.
II. Assess whether calcium-regulated changes in parathyroid hormone secretion predict changes in bone formation.
III. Characterize the response to GH in cancellous bone and in growth plate cartilage in patients with secondary hyperparathyroidism during calcitriol therapy.
|Condition or disease||Intervention/treatment||Phase|
|Renal Osteodystrophy End Stage Renal Disease||Drug: calcitriol Drug: growth hormone||Phase 2|
PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by bone lesion turnover and secondary hyperparathyroidism.
Patients in the first group are treated with recombinant human growth hormone subcutaneously every day for 8 months.
Patients in the second group are treated with calcitriol for 8 months, administered as a daily oral dose or an intraperitoneal dose three times a week.
Patients in the third group are treated with growth hormone and calcitriol (same dosages as above).
A control group does not receive any hormonal therapy.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||109 participants|
|Study Start Date :||June 1995|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004340
|United States, California|
|University of California Los Angeles School of Medicine|
|Los Angeles, California, United States, 90095|
|Study Chair:||Isidro B. Salusky||University of California, Los Angeles|